Phase 3 clarity could revive battered microcap HIT story

CVKD’s next credible upside catalyst is not new efficacy data but a company update that converts the March 2026 FDA End-of-Phase 2 meeting into a clearer Phase 3 path for CAD-1005 in HIT. The stock is tiny, thinly traded, and heavily de-risked on valuation after a major drawdown, so even a modestly positive protocol-finalization or Phase 3 initiation update could re-rate shares sharply. The main constraint is financing risk, which could cap upside or create dilution before or alongside the catalyst.

Cadrenal’s investable near-term story has shifted decisively to CAD-1005, its investigational selective 12-LOX inhibitor for suspected heparin-induced thrombocytopenia (HIT). The key facts are already known: Phase 2 results were reported in February 2026, the primary endpoint was not validated, but the secondary signal on thrombotic events was encouraging enough to support an End-of-Phase 2 FDA meeting completed on March 26, 2026. That makes the next meaningful stock-moving event a regulatory-development update, not a fresh data readout. Specifically, investors should watch for management to disclose how FDA feedback reshaped the pivotal Phase 3 design, what endpoint will anchor registration, and whether the company can outline timing to start the study. For a microcap with only about a $12M market cap, a clarified registrational path in an orphan indication can matter more than incremental science because it reduces uncertainty around whether the asset is actually developable. The setup is attractive because the float is small and the stock has already collapsed from much higher levels, leaving room for a sentiment rebound if management presents a credible, FDA-informed Phase 3 plan. However, this is still a high-risk setup: cash was only $4.0M at year-end 2025, the company explicitly said it is evaluating financing and strategic alternatives, and any development progress may be paired with dilution. So the likely trade is event-driven rather than fundamental. If Cadrenal announces finalized Phase 3 protocol details or a concrete initiation path for CAD-1005, the shares could move materially higher on improved regulatory clarity, orphan-drug scarcity value, and microcap momentum.